OrcaGraft (Orca-Q)

Phase 1Biologic

OOrca Biosystems, Inc.

OrcaGraft (Orca-Q) is one of 53 biologic programs targeting Acute Myeloid Leukemia. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Acute Myeloid LeukemiaRecruiting

Acute Myeloid LeukemiaPhase 1

Recruiting

Competition

Competitive Landscape

255 competitors in Acute Myeloid Leukemia

#DrugCompanyPhaseTrials

Idamycin

Pfizer

Phase 3

59 2

Novantrone

Pfizer

Phase 3

34 3

Xospata

Astellas

Phase 3

24 4

Fludara

Sanofi

Phase 3

17 5

Cerubidine

EEastern Cooperative Oncology Group

Phase 3

42 6

Vepesid

AAvyxa

Phase 3

52 7

Mylotarg

WWyeth-Lederle Vaccines

Phase 3

38 8

Vanflyta

Daiichi Sankyo

Phase 3

14 9

Neupogen

EEastern Cooperative Oncology Group

Phase 3

31 10

Cerubidine

HHikma Pharmaceuticals LLC

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2027

Phase 1Recruiting

Acute Myeloid Leukemia

NCT03802695

Clinical

Trials by Indication[1]

Acute Myeloid Leukemia1 trial

A Phase 1 Dose Escalation and Expansion Study of Orca-Q, an Engineered Donor Graft Derived From Mobilized Peripheral Blood, in Recipients Undergoing Allogeneic Hematopoietic Cell Transplantation for Hematologic Malignancies

Recruiting·OOrca Biosystems, Inc.·Phase 1·NCT03802695·300 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for OrcaGraft (Orca-Q). U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — OrcaGraft (Orca-Q) compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for OrcaGraft (Orca-Q). EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Orca Biosystems, Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Phase 1[1]
Company: OOrca Biosystems, Inc.

OrcaGraft (Orca-Q)

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2027

Trials by Indication[1]

Acute Myeloid Leukemia1 trial

References

Drug Info

Quick Facts

Related News